Initial Results From the Phase III BOSTON Study for Multiple Myeloma
Selinexor, the orally bioavailable first-in-class selective inhibitor of nuclear export (SINE) was initially approved by the FDA in July 2019 in combination with dexamethasone for previously treated patients with relapsed or refractory multiple myeloma. Currently, in the phase III BOSTON trial (NCT03110562), which is a two-arm, randomized, active comparator-controlled, open-label, multicenter…
